Current Edition

bio

Bluebird Bio has ‘doubts’ about continuing to do business through 2022, announces CFO resignation

With two of its prized gene therapies on clinical hold and another, Zynteglo, pulled from the market in Europe seven months ago after it was …

Continue Reading →
cancer

ASH: Senti Bio’s gene circuit CAR-NK cell therapy enhances cancer killing and safety in leukemia models

Engineered cell therapy has revolutionized the treatment of blood cancers, but precisely selecting the right target to kill off cancer cells while sparing healthy cells …

Continue Reading →
bolster

Patient Registries to Bolster Cell- and Gene-Therapy Clinical Trial Data

As the first personalized cell and gene therapies are approved from small clinical trials, researchers propose the creation of publicly accessible databases to pull together …

Continue Reading →
clinic

New Analysis Shows High Rates of Skin Clearance as Measured by Absolute PASI in Patients With Moderate to Severe Plaque Psoriasis Treated With Janssen’s TREMFYA® (guselkumab)

Janssen-Cilag International NV (“Janssen”) presented a new analysis from VOYAGE 1 assessing efficacy responses based on absolute Psoriasis Area and Severity Index score (PASI), as …

Continue Reading →